Preparation and in vitro characterization of AL-Beads containing carbamazepine and/or levetiracetam

The purpose of the present study was to prepare only levetiracetam (LEV) or carbamazepine (CBZ) or their combination (LEV+CBZ)-loaded alginate (AL) beads for oral administration to treat epilepsy and to evaluate their in vitro characteristics. AL beads were prepared using ionotropic gelation method...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Research in Pharmacy 2019-01, Vol.23 (4), p.642-651
Hauptverfasser: KANDİLLİ, Büşra, ÇETİN, Meltem, DEMİRKAYA MİLOĞLU, Fatma, UĞUR, Afife Büşra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The purpose of the present study was to prepare only levetiracetam (LEV) or carbamazepine (CBZ) or their combination (LEV+CBZ)-loaded alginate (AL) beads for oral administration to treat epilepsy and to evaluate their in vitro characteristics. AL beads were prepared using ionotropic gelation method and lyophilized. The bead formulations were evaluated for particles size, surface morphology, encapsulation efficiency and in vitro drug release in PB pH 6.8 and HCl pH 1.2 release mediums. FT-IR was also used to characterize the beads. The mean particle sizes of wet and lyophilized AL beads were in range of 1.609±0.073-1.779±0.078 mm and 1.075±0.182-1.275±0.138 mm, respectively. The encapsulation efficiency (EE%) values of bead formulations were in the range of 18.74-24.65% for LEV and 90.36-94.03% for CBZ. The pH of the medium affects the swelling behaviours of AL beads and the degree of swelling of AL beads increased with increase of pH of release medium, due to exchange of the Ca2+ ion with Na+. Besides, the pH of the release medium and the high water solubility of LEV affected the drug release rate from beads. AL beads might be useful to use for oral administration of LEV and CBZ to obtain additive/synergistic effect in a combined treatment of epilepsy.
ISSN:2630-6344
2630-6344
DOI:10.12991/jrp.2019.172